menu
    • menu
    [{"orgOrder":0,"company":"EPI Health","sponsor":"MC2 Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"","productType":"Small molecule","year":"2020","type":"Collaboration","leadProduct":"Calcipotriol","moa":"Vitamin D3 receptor","graph1":"Dermatology","graph2":"Approved","graph3":"EPI Health","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"EPI Health \/ MC2 Therapeutics","highestDevelopmentStatusID":"12","companyTruncated":"EPI Health \/ MC2 Therapeutics"},{"orgOrder":0,"company":"EPI Health","sponsor":"MC2 Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Calcipotriol","moa":"Vitamin D receptor","graph1":"Dermatology","graph2":"Approved","graph3":"EPI Health","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"EPI Health \/ MC2 therapeutics","highestDevelopmentStatusID":"12","companyTruncated":"EPI Health \/ MC2 therapeutics"},{"orgOrder":0,"company":"EPI Health","sponsor":"Novan","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Berdazimer Sodium","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"EPI Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Gel","sponsorNew":"EPI Health \/ EPI Health","highestDevelopmentStatusID":"10","companyTruncated":"EPI Health \/ EPI Health"},{"orgOrder":0,"company":"EPI Health","sponsor":"Sato Yakuhin Kogyo Co., Ltd","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"","productType":"Small molecule","year":"2022","type":"Licensing Agreement","leadProduct":"Oxymetazoline Hydrochloride","moa":"","graph1":"Dermatology","graph2":"Approved","graph3":"EPI Health","amount2":0.01,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0.01,"dosageForm":"Cream","sponsorNew":"EPI Health \/ Sato Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"EPI Health \/ Sato Pharmaceutical"}]

    Find Clinical Drug Pipeline Developments & Deals by EPI Health

    Menu

    EPI Health

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            EPI Health

                            U.S.A arrow
                            euroPLX 86 Munich
                            Not Confirmed

                            EPI Health

                            U.S.A arrow
                            euroPLX 86 Munich
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Oxymetazoline Hydrochloride

                            Therapeutic Area : Dermatology

                            Study Phase : Approved

                            Sponsor : Sato Yakuhin Kogyo Co., Ltd

                            Deal Size : $7.5 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            EPI Health, a Novan Company, Enters into Exclusive License Agreement with Sato Pharmaceutical Co., Ltd. for RH...

                            Details : Rhofade (oxymetazoline hydrochloride) cream is an FDA-approved prescription topical treatment that may reduce persistent facial redness by at least two grades, according to both doctor and patient scales that evaluated rosacea redness in two 29-day trial...

                            Brand Name : Rhofade

                            Molecule Type : Small molecule

                            Upfront Cash : $5.0 million

                            December 21, 2022

                            Lead Product(s) : Oxymetazoline Hydrochloride

                            Therapeutic Area : Dermatology

                            Highest Development Status : Approved

                            Sponsor : Sato Yakuhin Kogyo Co., Ltd

                            Deal Size : $7.5 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            EPI Health

                            U.S.A arrow
                            euroPLX 86 Munich
                            Not Confirmed

                            EPI Health

                            U.S.A arrow
                            euroPLX 86 Munich
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Berdazimer Sodium

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase III

                            Recipient : Novan

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Novan and EPI Health, a Novan Company, Announce Abstracts Accepted for Poster Presentation at the 42nd Annual ...

                            Details : WYNZORA Cream is a fixed dose combination of calcipotriene and betamethasone dipropionate used for the topical treatment of plaque psoriasis. Betamethasone dipropionate has anti-inflammatory effects resulting in decreased expression of key TNF-α, IL-17A...

                            Brand Name : SB206

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            October 14, 2022

                            Lead Product(s) : Berdazimer Sodium

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase III

                            Recipient : Novan

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            EPI Health

                            U.S.A arrow
                            euroPLX 86 Munich
                            Not Confirmed

                            EPI Health

                            U.S.A arrow
                            euroPLX 86 Munich
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Calcipotriol,Betamethasone Dipropionate

                            Therapeutic Area : Dermatology

                            Study Phase : Approved

                            Sponsor : MC2 Therapeutics

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            EPI Health, a Novan Company, and MC2 Therapeutics Present WYNZORA® (calcipotriene and betamethasone dipropion...

                            Details : WYNZORA is a cream-based fixed dose combination of calcipotriene and betamethasone dipropionate for topical treatment of plaque psoriasis. It is based on PAD™ Technology, which enables stability of both calcipotriene and betamethasone dipropionate in a...

                            Brand Name : Wynzora

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            September 15, 2022

                            Lead Product(s) : Calcipotriol,Betamethasone Dipropionate

                            Therapeutic Area : Dermatology

                            Highest Development Status : Approved

                            Sponsor : MC2 Therapeutics

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            EPI Health

                            U.S.A arrow
                            euroPLX 86 Munich
                            Not Confirmed

                            EPI Health

                            U.S.A arrow
                            euroPLX 86 Munich
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Calcipotriol,Betamethasone Dipropionate

                            Therapeutic Area : Dermatology

                            Study Phase : Approved

                            Sponsor : MC2 Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            MC2 Therapeutics Announces Collaboration with EPI Health on Commercialization of Newly Approved Psoriasis Drug...

                            Details : Collaboration accelerates a Q1 2021 comprehensive launch of MC2’s WYNZORA® Cream to patients with plaque psoriasis in the US. WYNZORA® Cream is the first drug based on PADTM Technology – providing innovative solutions to unmet needs in chronic infl...

                            Brand Name : Wynzora

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            August 24, 2020

                            Lead Product(s) : Calcipotriol,Betamethasone Dipropionate

                            Therapeutic Area : Dermatology

                            Highest Development Status : Approved

                            Sponsor : MC2 Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth